| Literature DB >> 18831032 |
Fulvia Brugnoletti1, E Brannon Morris, Fred H Laningham, Zoltán Patay, Jennifer L Pauley, Ching-Hon Pui, Sima Jeha, Hiroto Inaba.
Abstract
Systemic and intrathecal methotrexate (MTX) are integral components of acute lymphoblastic leukemia (ALL) therapy, but can be associated with neurotoxicity. We describe here the case of an adolescent male with T-cell ALL who developed recurrent episodes of subacute neurotoxicity characterized by slurred speech, emotional lability, and hemiparesis after intrathecal MTX administration. Serial magnetic resonance imaging with diffusion-weighted imaging showed recurrent areas of restricted diffusion within cerebral hemispheric white matter, which correlated chronologically with the administration of intrathecal therapy and severity of clinical symptoms. Resolution of diffusion abnormalities did not preclude further toxicity and a large lesion could cause persisting symptoms. (c) 2008 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2009 PMID: 18831032 PMCID: PMC2605174 DOI: 10.1002/pbc.21764
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN: 1545-5009 Impact factor: 3.167